Table 4 Univariate comparison of characteristics of patients who were anticoagulated and those who were not anticoagulated
Characteristic | Anticoagulated (n= 36) | Not anticoagulated (n= 81) | P |
|---|---|---|---|
|  | Mean ± SD or n (%) | Mean ± SD or n (%) |  |
Female | 34 (94.4%) | 71(87.6%) | 0.26 |
Age at CTD diagnosis, years | 48.5 ± 14.3 | 51.1 ± 14.7 | 0.46 |
Age at PAH diagnosis*, years | 59.7 ± 13.1 | 62.5 ± 10.6 | 0.23 |
Anti-phospholipid antibodies | 8 (22.1%) | 19 (23.5%) | 0.74 |
Contraindication to anticoagulation | 0 (0%) | 18 (22.2%) | 0.002 |
WHO functional class | Â | Â | Â |
Class I | 0 (0%) | 9 (11.1%) | Â |
Class II | 3 (8.3%) | 11 (13.6%) | 0.09 |
Class III | 32 (88.9%) | 56 (69.1%) | Â |
Class IV | 1 (2.8%) | 5 (6.2%) | Â |
Baseline 6MWD, m | 286.3 ± 116.4 | 339.5 ± 128.4 | 0.06 |
Baseline mRAP, mmHg | 7.1 ± 4.3 | 6.9 ± 4.1 | 0.85 |
Baseline mPAP, mmHg | 42.0 ± 11.5 | 33.4 ± 12.0 | 0.001 |
Pericardial effusion | 9 (25.0%) | 5 (6.2%) | 0.004 |
Pulmonary vasodilator therapy | Â | Â | Â |
   Monotherapy | 13 (36.1%) | 57 (71.3%) |  |
   Sequential monotherapy | 2 (5.6%) | 10 (12.5%) | < 0.0001 |
   Combination therapy | 21 (58.3%) | 13 (16.3%) |  |